Roger Perlmutter’s new gig, Covid-19 IP drama, Vivek Ramaswamy's coach on the SPAC train, and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
The email version of Endpoints Weekly has now crossed the 10,000 subscriber mark. Thanks for being the first readers to sign up. Your feedback and thoughts are always welcome — my email is just below.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.